Skip to main content
    E

    EXACT Sciences Corporation (EXAS)

    Official site

    DIAGNOSTICS & RESEARCH

    $104.91
    +0.00 (+0.00%)

    Last updated: Mar 24, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(27/37)
    Avg Surprise
    +7.44%

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$0.28
    Range$0.28 - $0.28
    1 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.31-8.4%
    60d ago$0.31-8.4%
    30d ago$0.30-7.7%
    7d ago$0.30-7.7%
    Current$0.28
    Revenue Consensus
    $917M
    Range$880M - $944M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-$0.28---
    Dec 25
    Reported Feb 13
    		$-0.21$0.08-362.50%Miss+12.6%
    Sep 25
    Reported Nov 3
    		$0.24$0.16+50.00%Beat+214.3%
    Jun 25
    Reported Aug 6
    		$-0.01N/A+92.31%Beat+83.3%
    Mar 25
    Reported May 6
    		$-0.36$-0.47+23.83%Beat+33.7%
    Dec 24
    Reported Feb 19
    		$-0.24$-0.33+27.74%Beat+44.1%
    Sep 24
    Reported Nov 5
    		$-0.21$-0.21+0.00%Beat+34.4%
    Jun 24
    Reported Jul 31
    		$-0.06N/A+75.00%Beat+82.9%
    Mar 24
    Reported May 8
    		$-0.54$-0.41-31.71%Miss-54.3%
    Dec 23
    Reported Feb 21
    		$-0.43$-0.36-19.44%Miss+23.2%
    Sep 23
    Reported Nov 1
    		$-0.32$-0.43+25.58%Beat+56.8%
    Jun 23
    Reported Aug 1
    		$-0.35$-0.41+14.63%Beat+62.4%
    Mar 23
    Reported May 9
    		$-0.35$-0.66+46.97%Beat+70.3%
    Dec 22
    Reported Feb 21
    		$-0.56$-0.78+28.21%Beat+56.3%
    Sep 22
    Reported Nov 3
    		$-0.74$-1.05+29.52%Beat+0.0%
    Jun 22
    Reported Aug 2
    		$-0.93$-1.04+10.58%Beat-22.4%
    Mar 22
    Reported Apr 26
    		$-1.18$-1.04-13.46%Miss-1585.7%
    Dec 21
    Reported Feb 22
    		$-1.28$-0.88-45.45%Miss-1180.0%
    Sep 21
    Reported Nov 2
    		$-0.74$-0.83+10.84%Beat-1380.0%
    Jun 21
    Reported Jul 28
    		$-0.76$-0.72-5.56%Miss-10.1%
    Mar 21
    Reported May 4
    		$-0.07N/A+92.55%Beat+89.4%
    Dec 20
    Reported Feb 16
    		$-0.10N/A+61.54%Beat+86.8%
    Sep 20
    Reported Oct 27
    		$-0.05N/A+91.23%Beat+83.9%
    Jun 20
    Reported Jul 30
    		$-0.69$-0.65-6.15%Miss-130.0%
    Mar 20
    Reported May 6
    		$-0.66$-0.52-26.92%Miss+0.0%
    Dec 19
    Reported Feb 11
    		$-0.76$-0.36-111.11%Miss-72.7%
    Sep 19
    Reported Oct 29
    		$-0.31$-0.41+24.39%Beat+16.2%
    Jun 19
    Reported Jul 29
    		$-0.30$-0.56+46.43%Beat+0.0%
    Mar 19
    Reported Apr 30
    		$-0.66$-0.65-1.54%Miss-100.0%
    Dec 18
    Reported Feb 21
    		$-0.44$-0.48+8.33%Beat-144.4%
    Sep 18
    Reported Oct 30
    		$-0.37$-0.43+13.95%Beat-60.9%
    Jun 18
    Reported Aug 1
    		$-0.30$-0.32+6.25%Beat-11.1%
    Mar 18
    Reported Apr 26
    		$-0.33$-0.38+13.16%Beat-3.1%
    Dec 17
    Reported Feb 22
    		$-0.18$-0.24+25.00%Beat+47.1%
    Sep 17
    Reported Oct 30
    		$-0.23$-0.30+23.33%Beat-
    Jun 17
    Reported Jul 25
    		$-0.27$-0.35+22.86%Beat-
    Mar 17
    Reported Apr 27
    		$-0.32$-0.41+21.95%Beat-
    Dec 16
    Reported Feb 21
    		$-0.34$-0.39+12.82%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$104.04
    SMA 20$103.72
    SMA 50$103.14
    SMA 200$74.80
    EMA 10$104.23
    EMA 20$103.86
    EMA 50$101.87
    EMA 200$81.46

    MACD

    Line: 0.48Signal: 0.38Hist: 0.10

    ADX

    ADX: 46.8+DI: 38.4-DI: 6.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down32.0
    PSAR$103.49

    Bollinger Bands

    Upper Band$104.83
    Lower Band$102.61
    %B Position214%(Upper)
    Band Width1.03

    RSI (14-Day)

    Overbought
    76.4

    Momentum Oscillators

    Stoch %K96.1
    Stoch %D92.8
    Williams %R-4.0
    ROC (10d)1.5%
    Momentum1.54
    CCI (20d)192.8
    MFI (14d)79.6

    Volatility Measures

    ATR (14d)$0.32(0.3%)
    StdDev (20d)0.56
    Hist Vol4.2%(Low)

    Volume Flow

    VWAP$104.91
    OBV225.9M
    AD Line-47.7M
    CMF (20d)-0.162

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol RatioN/A
    VWMA (20d)$104.03

    Pivot Points

    R3$104.91
    R2$104.91
    R1$104.91
    Pivot Point$104.91
    S1$104.91
    S2$104.91
    S3$104.91

    Advanced Oscillators

    TSI39.85
    Ultimate Osc73.4
    KST9.22

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$878.38M$850.74M$811.09M$706.78M$713.42M$708.65M$699.26M$637.52M$646.88M$628.34M$622.09M$602.45M
    Cost of Revenue$262.56M$266.81M$248.63M$206.24M$220.83M$217.17M$210.95M$191.20M$255.18M$168.53M$156.99M$156.87M
    Gross Profit$615.83M$583.93M$562.45M$500.55M$492.59M$491.49M$488.32M$446.32M$391.70M$459.81M$465.10M$445.58M
    Operating Expenses$698.42M$609.47M$564.60M$596.56M$1.37B$530.89M$514.57M$553.01M$459.55M$452.96M$542.03M$522.67M
    R&D$191.50M$117.29M$108.90M$105.31M$97.71M$101.49M$121.14M$110.87M$115.97M$111.45M$104.09M$95.42M
    SG&A$217.99M$241.41M$208.58M$220.69M$191.11M$193.54M$177.52M$219.65M$127.64M$217.39M$237.97M$217.29M
    Operating Income$-82,595,000$-25,545,000$-2,148,000$-96,010,000$-876,351,000$-39,403,000$-26,257,000$-106,692,000$-67,841,000$6.85M$-76,929,000$-77,091,000
    Interest Income$0$0$0$0$0$0$0$0$0$2.06M$4.83M$0
    Interest Expense$9.76M$9.79M$9.84M$9.98M$9.58M$9.61M$-111,000$7.94M$7.87M$7.87M$7.82M$-4,107,000
    Income Before Tax$-85,083,000$-17,757,000$-57,000$-100,991,000$-875,966,000$-37,428,000$-14,345,000$-108,422,000$-50,376,000$1.04M$-79,919,000$-72,494,000
    Income Tax Expense$872,000$1.84M$1.13M$224,000$-11,381,000$808,000$1.46M$1.81M$-610,000$249,000$1.11M$1.66M
    Net Income$-85,955,000$-19,594,000$-1,185,000$-101,215,000$-864,585,000$-38,236,000$-15,808,000$-110,228,000$-49,766,000$794,000$-81,026,000$-74,151,000
    EBITDA$-18,971,000$47.91M$65.06M$-36,952,000$-823,204,000$26.95M$38.54M$-46,536,000$-13,669,000$59.10M$-26,490,000$-27,348,000
    EBIT$-75,324,000$-7,968,000$9.78M$-91,013,000$-876,351,000$-27,821,000$-14,456,000$-100,479,000$-67,841,000$6.85M$-76,929,000$-77,091,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about EXAS

    News

    Exact Sciences stock trades steady as colorectal screening momentum meets earnings pressure

    Exact Sciences stock is stable, balancing strong growth in its colorectal cancer screening business with ongoing net losses. Investors are keenly observing total revenue growth, which has been in double digits...

    Ad-hoc-news.de•7/27/26•Neutral

    Exact Sciences stock trades steadily as revenue grows and screening portfolio expands

    Exact Sciences stock is maintaining steady trade due to increasing revenue and an expanding cancer screening portfolio...

    Ad-hoc-news.de•7/24/26•Bullish

    Exact Sciences stock trades steady as revenue growth and screening demand support valuation

    Exact Sciences' stock is holding steady, driven by strong double-digit revenue growth and increasing demand for its diagnostic tests...

    Ad-hoc-news.de•7/22/26•Bullish

    Exact Sciences stock trades near recent highs as screening demand supports revenue growth

    Exact Sciences' stock is trading near recent highs, driven by strong demand for its cancer screening tests, particularly the Cologuard colorectal cancer test. The company has reported double-digit revenue growth...

    Ad-hoc-news.de•7/22/26•Bullish

    Exact Sciences stock trades steadily as screening growth offsets guidance reset

    Exact Sciences' stock performance is driven by a balance of strong cancer screening demand and adjusted revenue guidance. The company’s flagship products, Cologuard and Oncotype DX, continue to show significant growth...

    ad-hoc-news.de•7/20/26•Somewhat-Bullish

    EXAS Competitors

    CompanyTicker
    Viatris IncVTRS
    Zimmer Biomet Holdings IncZBH
    STERIS plcSTE
    Hologic IncHOLX
    Insmed IncINSM
    Medpace Holdings IncMEDP
    Tenet Healthcare CorporationTHC
    Revvity Inc.RVTY

    Sector: Healthcare

    EXAS Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -15.7%
    EPS estimate (fiscal period ending Jun 30, 2026)
    $0.28
    Estimate revisions (30 days, fiscal period ending Jun 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About EXAS

    Does EXAS pay dividends?

    EXACT Sciences Corporation (EXAS) does not currently pay a regular dividend.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In